A major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the
accumulation of disability over an often decades-long disease course. Disability progression …

Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a
smoldering inflammatory activity is present from the earliest stages of the disease and …

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …

Background and Objectives Progression independent of relapse activity (PIRA) is a crucial
determinant of overall disability accumulation in multiple sclerosis (MS). Accelerated brain …

Importance Although up to 20% of patients with multiple sclerosis (MS) experience onset
before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) …

Background and purpose Newly appearing lesions in multiple sclerosis (MS) may evolve
into chronically active, slowly expanding lesions (SELs), leading to sustained disability …

Background Observational studies have suggested an association between multiple
sclerosis (MS) and cortical structure, but the results have been inconsistent. Objective We …

Chronic low-grade inflammation and neuronal deregulation are two components of a
smoldering disease activity that drives the progression of disability in people with multiple …

Multiple sclerosis (MS) is a heterogeneous neurological disorder with regards to clinical
presentation and pathophysiology. Here, we investigated the heterogeneity of MS by …

Background Cognitive impairment (CI) is a common symptom in multiple sclerosis (MS)
patients. Cortical damages can be closely associated with cognitive network dysfunction and …